Ser119

Site Information
EILsRRPsyRkILND SwissProt Entrez-Gene
Blast this site against: NCBI SwissProt PDB
Site Group ID: 448228
Associated spectra: 2 CST

In vivo Characterization
Methods used to characterize site in vivo:	electrophoretic mobility shift ( 58 , 155 ) , flow cytometry ( 30 ) , immunoassay ( 1 , 2 , 15 , 19 ) , immunoprecipitation ( 18 , 38 , 45 , 53 , 62 , 80 , 133 , 160 ) , mass spectrometry ( 18 , 32 , 43 , 44 , 52 , 55 , 56 , 57 , 60 , 66 , 67 , 68 , 69 , 74 , 75 , 76 , 77 , 78 , 79 , 82 , 83 , 84 , 85 , 86 , 87 , 88 , 89 , 90 , 91 , 92 , 93 , 94 , 95 , 97 , 98 , 99 , 100 , 101 , 102 , 103 , 104 , 105 , 106 , 108 , 109 , 110 , 111 , 112 , 113 , 123 , 124 ) , mutation of modification site ( 27 , 29 , 38 , 58 , 62 , 80 , 122 , 127 , 129 , 134 , 139 , 140 , 149 , 159 ) , phospho-antibody ( 1 , 2 , 3 , 4 , 5 , 6 , 7 , 8 , 9 , 10 , 11 , 12 , 14 , 15 , 16 , 17 , 19 , 20 , 21 , 22 , 23 , 25 , 26 , 27 , 28 , 29 , 30 , 31 , 32 , 33 , 34 , 35 , 36 , 37 , 38 , 39 , 40 , 41 , 42 , 45 , 46 , 47 , 49 , 50 , 51 , 53 , 54 , 59 , 61 , 62 , 63 , 64 , 71 , 72 , 73 , 81 , 107 , 115 , 116 , 117 , 118 , 119 , 120 , 121 , 122 , 125 , 126 , 128 , 129 , 130 , 132 , 133 , 134 , 135 , 136 , 137 , 138 , 141 , 142 , 143 , 144 , 145 , 146 , 147 , 148 , 150 , 151 , 152 , 153 , 154 , 155 , 156 , 157 , 158 , 159 , 160 , 162 , 163 , 164 , 166 ) , western blotting ( 1 , 3 , 4 , 5 , 6 , 7 , 8 , 9 , 10 , 11 , 12 , 14 , 15 , 16 , 17 , 18 , 19 , 20 , 21 , 22 , 23 , 25 , 26 , 27 , 28 , 29 , 30 , 31 , 32 , 33 , 34 , 35 , 36 , 37 , 38 , 39 , 40 , 41 , 42 , 45 , 46 , 47 , 49 , 50 , 51 , 53 , 54 , 58 , 59 , 61 , 62 , 63 , 64 , 71 , 72 , 80 , 81 , 107 , 115 , 116 , 117 , 118 , 120 , 121 , 122 , 126 , 129 , 133 , 137 , 138 , 142 , 143 , 144 , 145 , 147 , 150 , 151 , 152 , 153 , 154 , 156 , 158 , 159 , 160 , 162 , 163 , 166 )
Disease tissue studied:	adrenal cancer ( 10 ) , pheochromocytoma ( 10 ) , bladder cancer ( 30 , 35 ) , breast cancer ( 9 , 18 , 72 , 151 ) , breast adenocarcinoma ( 9 ) , colorectal cancer ( 38 ) , colorectal carcinoma ( 38 ) , gastric cancer ( 52 , 66 , 67 , 115 ) , gastric carcinoma ( 52 , 66 , 67 , 115 ) , kidney cancer ( 150 ) , leukemia ( 58 , 60 , 124 , 129 , 138 , 154 ) , acute erythroid leukemias, including erythroleukemia (M6a) and very rare pure erythroid leukemia (M6b) ( 154 ) , chronic myelogenous leukemia ( 58 , 60 , 124 , 138 ) , T cell leukemia ( 129 ) , liver cancer ( 3 , 12 , 25 , 32 , 38 , 63 , 158 ) , liver adenocarcinoma ( 38 ) , hepatocellular carcinoma ( 3 ) , lung cancer ( 17 , 26 , 31 , 40 , 69 , 73 , 81 ) , non-small cell lung cancer ( 17 , 26 , 31 , 40 , 69 , 73 ) , non-small cell lung adenocarcinoma ( 17 , 26 , 31 , 69 ) , non-small cell squamous cell lung carcinoma ( 69 ) , lymphoma ( 23 , 107 ) , Burkitt's lymphoma ( 107 ) , neuroblastoma ( 14 , 15 , 34 , 58 , 162 ) , ovarian cancer ( 47 ) , pancreatic cancer ( 8 , 116 , 137 ) , pancreatic carcinoma ( 116 , 137 ) , prostate cancer ( 4 , 29 , 45 , 51 , 126 ) , melanoma skin cancer ( 6 , 21 , 28 , 49 ) , small intestine sarcoma ( 1 ) , testicular cancer ( 54 , 121 ) , psoriasis ( 119 )
Relevant cell line - cell type - tissue:	'3T3-L1, differentiated' (adipocyte) ( 39 ) , 'brain, cerebral cortex' ( 15 , 41 ) , 'brain, hippocampus' ( 20 ) , 'brain, hypothalamus, medial preoptic area' ( 135 ) , 'muscle, skeletal' ( 42 , 117 ) , 'neuron, cerebellar granule'-brain ( 160 ) , 'neuron, cortical' ( 2 , 34 ) , 'neuron, cortical'-brain ( 27 , 130 ) , 'neuron, hippocampal'-brain ( 130 ) , 1-LN (prostate cell) ( 45 ) , 293 (epithelial) [DYRK3 (mouse)] ( 148 ) , 293 (epithelial) ( 15 , 18 , 53 , 62 , 83 , 84 , 85 , 86 , 132 , 133 , 134 , 144 , 147 , 149 , 162 ) , 293FT ( 11 ) , A431 (epithelial) [PRKD1 (human)] ( 122 ) , A431 (epithelial) ( 13 ) , A549 (pulmonary) ( 17 , 31 ) , adipose tissue ( 11 ) , AGS (gastric) ( 115 ) , AML12 (hepatic) ( 3 ) , AtT20 (pituitary cell) ( 136 ) , B lymphocyte-blood ( 129 ) , C3H10T1/2 (fibroblast) ( 80 ) , C8161 (melanocyte) ( 49 ) , CAL-120 (breast cell) ( 9 ) , CHO (fibroblast) ( 64 ) , chromaffin-adrenal gland ( 141 , 153 ) , CL1-5 (pulmonary) ( 31 ) , COLO-357 (pancreatic) ( 8 ) , COS (fibroblast) ( 46 , 122 , 127 , 159 , 163 ) , DFCI032 ( 17 ) , DU 145 (prostate cell) ( 45 ) , fibroblast-lung ( 16 ) , fibroblast-skin ( 16 ) , H9c2 (myoblast) ( 5 ) , HCT116 (intestinal) ( 38 ) , HEK293-A (epithelial) ( 3 , 17 ) , HEK293T (epithelial) [SOX9 (human), transfection] ( 80 ) , HEK293T (epithelial) ( 46 , 107 ) , HeLa (cervical) [5-HT(7) (human), transgenic] ( 125 ) , HeLa (cervical) ( 18 , 33 , 61 , 68 , 71 , 82 , 162 ) , hepatocyte ( 3 , 133 ) , HepG2 (hepatic) ( 12 , 25 , 32 , 63 , 158 , 163 ) , HIT-T15 (pancreatic) ( 116 , 137 ) , HOS (bone cell) ( 146 ) , Huh7 (hepatic) ( 3 ) , HUVEC (endothelial) ( 22 , 156 ) , J82 (bladder cell) ( 35 ) , Jurkat (T lymphocyte) ( 43 , 55 , 56 , 57 , 74 , 75 , 76 , 77 , 78 , 79 , 87 , 88 , 89 , 90 , 91 , 92 , 93 , 94 , 95 , 97 , 98 , 99 , 100 , 101 , 102 , 103 , 104 , 105 , 106 , 108 , 109 , 110 , 111 , 112 , 113 , 123 , 143 ) , K562 (erythroid) ( 58 , 60 , 124 , 138 ) , keratinocyte-skin ( 118 , 119 ) , KGN (ovarian) ( 1 ) , Kit225 (T lymphocyte) ( 129 ) , L6 (myoblast) ( 42 ) , LNCaP (prostate cell) ( 4 , 29 , 51 , 126 ) , MCF-7 (breast cell) ( 18 , 72 ) , MCF10A1 (epithelial) ( 3 ) , MDA-MB-231 (breast cell) ( 151 ) , MDCK (epithelial) ( 152 ) , MEF (fibroblast) ( 30 , 39 ) , Melan-a (melanocyte) ( 49 ) , mesangial-kidney ( 150 ) , MKN-45 (gastric) ( 52 , 66 , 67 , 115 ) , myocyte-heart ( 5 ) , NCI-H1703 (squamous) ( 44 , 69 ) , NCI-H1975 (pulmonary) ( 26 ) , NCI-H441 (pulmonary) ( 40 , 81 ) , NCI-H460 (pulmonary) ( 73 ) , NMuMG (epithelial) ( 134 ) , NT2 (testicular) ( 54 , 121 ) , OV433 (ovarian) ( 47 ) , pancreatic acini ( 128 ) , PC-12 (chromaffin) ( 10 , 139 , 140 , 166 ) , PC3 (prostate cell) ( 29 , 45 , 142 ) , PREC (epithelial) ( 19 ) , prostate ( 4 , 142 ) , RAMOS (B lymphocyte) ( 107 ) , Rat2 (fibroblast) ( 145 ) , RB383 ( 7 ) , RMG1 (ovarian) ( 47 ) , RT4 (bladder cell) ( 35 ) , SH-SY5Y (neural crest) ( 14 , 15 , 34 , 58 , 120 , 155 ) , SK-HEP-1 (endothelial) ( 38 ) , SK-MEL-30 (melanocyte) ( 6 ) , SK-MEL2 (melanocyte) ( 28 ) , SK-N-MC (neural crest) ( 139 , 162 , 164 ) , SKNDZ (neural crest) ( 122 ) , SNU-1 (gastric) ( 115 ) , spinal cord ( 50 ) , SW480 (intestinal) ( 38 ) , T lymphocyte-blood ( 129 ) , T/C-28a2 (chondrocyte) ( 59 ) , T24 (bladder cell) ( 30 ) , TF-1 (erythroid) ( 154 ) , U-937 (myeloid) ( 23 ) , UMUC3 (bladder cell) ( 30 ) , WM115 (melanocyte) ( 21 )

Upstream Regulation
Regulatory protein:	5-HT(7) (human) ( 125 ) , ADM2 (human) ( 22 ) , AIF1 (mouse) ( 36 ) , AKIP (human) ( 53 ) , Akt1 (human) ( 115 ) , AR (human) ( 11 ) , CXADR (human) ( 7 ) , DARPP-32 (human) ( 115 ) , GADD45GIP1 (human) ( 22 ) , gp160 (retrovirus) ( 15 ) , GSK3B (human) ( 142 ) , HDAC1 (human) ( 147 ) , HIPK1 (human) ( 5 ) , JNK1 (mouse) ( 37 ) , LPAR4 (human) ( 8 ) , MSK1 (human) ( 126 ) , NFkB-p100 (human) ( 30 ) , NRas (human) ( 49 ) , NRas (mouse) ( 49 ) , p90RSK (human) ( 126 ) , PHLPP2 (human) ( 30 ) , PKACA (human) ( 10 ) , PKAR2B (human) ( 143 ) , PLCG1 (human) ( 9 ) , PTGER2 (human) ( 132 ) , PTGER2 (mouse) ( 59 ) , PTGER3 (mouse) ( 59 ) , PTGER4 (human) ( 132 ) , RhoGDI alpha (human) ( 22 ) , ROR2 (human) ( 4 ) , S100B (human) ( 21 ) , SFRP2 (human) ( 7 ) , SPRED2 (human) ( 6 ) , TORC1 (human) ( 144 ) , TORC2 (human) ( 144 ) , TRPC7 (mouse) ( 46 ) , WNT5A (human) ( 72 )
Putative in vivo kinases:	Akt1 (human) ( 8 , 14 ) , ATM (human) ( 120 ) , DYRK3 (mouse) ( 148 ) , MAPKAPK2 (human) ( 163 , 164 ) , MSK1 (human) ( 119 , 159 ) , MSK2 (human) ( 119 ) , p90RSK (human) ( 163 ) , PKACA (mouse) ( 20 , 23 ) , PKCE (human) ( 154 ) , PRKD1 (human) ( 122 ) , RSK2 (human) ( 163 ) , RSK3 (human) ( 163 ) , SGK1 (mouse) ( 134 )
Kinases, in vitro:	ATM (human) ( 120 ) , CAMK4 (human) ( 61 ) , Cot (human) ( 70 ) , MAPKAPK2 (human) ( 164 ) , MSK1 (human) ( 63 , 65 , 162 ) , p90RSK (human) ( 162 ) , PKACA (human) ( 39 , 58 , 63 , 114 , 165 ) , PKACA (mouse) ( 61 ) , PRKD1 (human) ( 122 ) , SGK1 (human) ( 134 , 152 ) , TSSK4 (human) ( 131 )
Putative upstream phosphatases:	PTEN (human) ( 19 )
Treatments:	2-deoxyglucose ( 73 ) , 5-HT ( 125 ) , 6-((1-(4-nitrobenzyl)- 1H-1,2,3-triazol-4-yl)methyl ( 12 ) , 8-CPT-2Me-cAMP ( 45 ) , adriamycin ( 122 ) , AG1478 ( 151 ) , AH6809 ( 59 ) , AlCl3 ( 10 ) , androgen_withdrawal ( 29 ) , angiotensin ( 153 ) , anisomycin ( 119 , 146 ) , antibody ( 9 , 107 , 143 ) , arsenite ( 146 , 164 ) , ascomycin ( 141 ) , BayK8644 ( 64 ) , BDNF ( 160 ) , beta-amyloid_42 ( 14 ) , BI-D1870 ( 21 ) , bisindolylmaleimide_II ( 54 ) , BIX02188 ( 50 ) , cAMP_analog ( 53 , 116 , 128 , 158 ) , carbachol ( 46 ) , cigarette smoke extract ( 1 ) , cisplatin ( 47 ) , CL316,243 ( 11 ) , cocaine ( 41 ) , colforsin ( 28 , 29 , 61 , 72 , 81 , 96 , 120 , 121 , 133 , 137 , 139 , 143 , 144 , 147 , 150 , 157 , 162 , 164 , 166 ) , CRF ( 136 ) , D600 ( 141 ) , depolarization ( 64 , 137 , 141 , 166 ) , dexamethasone ( 40 , 134 ) , DHT ( 11 ) , dimethylfumarate ( 118 ) , EGF ( 126 , 155 , 157 , 159 , 162 , 163 ) , enzalutamide ( 4 ) , ethanol ( 15 ) , exercise ( 117 ) , FGF1 ( 9 , 164 ) , fluid_shear_stress ( 59 ) , fumaric_acid ( 118 ) , genistein ( 35 , 129 ) , GF109203X ( 154 , 156 ) , glucagon ( 25 ) , GM-CSF ( 154 ) , Go_6976 ( 122 ) , Go_6983 ( 122 ) , GSK-J4 ( 23 ) , GSK650394 ( 40 ) , H-7 ( 154 ) , H-89 ( 16 , 23 , 27 , 59 , 129 , 132 , 145 , 148 , 150 , 153 , 156 ) , H2O2 ( 138 ) , HA-1004 ( 154 ) , HGF ( 128 ) , histamine ( 61 ) , hypoxia ( 8 ) , IBMX ( 29 , 40 , 49 ) , ICG-001 ( 26 ) , IGF-1 ( 155 ) , IL-1b ( 118 , 119 ) , IL-2 ( 129 ) , IL-3 ( 154 ) , IL-4 ( 154 ) , insulin ( 14 , 25 , 42 , 81 ) , ionizing_radiation ( 26 , 120 , 138 , 151 ) , ionomycin ( 150 ) , ipatasertib ( 8 ) , KCl ( 2 ) , KG-501 ( 1 ) , KGF ( 19 ) , KN-62 ( 27 ) , KN-93 ( 129 , 153 ) , KT-5926 ( 150 ) , KT5720 ( 129 ) , kynurenine ( 31 ) , LIF ( 136 ) , linoleic_acid ( 42 ) , lithium ( 116 , 155 ) , losartan ( 153 ) , low_pH ( 16 ) , LPA ( 145 ) , LPS ( 26 , 48 ) , LY294002 ( 59 , 81 , 129 , 132 , 156 , 160 ) , methylhydrogenfumarate ( 118 ) , metribolone ( 19 , 51 ) , miR-200a-3p inhibitor ( 10 ) , morphine ( 50 ) , morphine_withdrawal ( 50 ) , MSH ( 49 ) , N-6-2- O-dibutyryladenosine 3' 5' -cyclic-monophosphosphate ( 40 ) , N6-benzoyl-cAMP ( 45 ) , nifedipine ( 64 ) , NKH_477 ( 3 , 11 , 16 , 17 , 40 , 49 ) , NMDA ( 130 ) , NPC-15342 ( 154 ) , NS398 ( 59 ) , NSC-127102 ( 63 ) , OAG ( 46 ) , Ogerin ( 16 ) , okadaic_acid ( 34 , 130 ) , oleic_acid ( 42 ) , ONOO(-) ( 64 ) , PD123319 ( 153 ) , PD98059 ( 23 , 145 , 146 , 154 , 156 , 160 , 162 ) , PDGF ( 122 , 163 ) , peptide ( 7 ) , phaeosphaeride A ( 13 ) , phenylephrine ( 5 ) , phorbol_ester ( 54 , 122 , 154 , 157 , 166 ) , PlGF ( 156 ) , PP1 ( 153 ) , prostaglandin_E ( 132 ) , PS48 ( 14 ) , pup exposure ( 135 ) , racepinefrine ( 3 ) , rapamycin ( 48 ) , retinoic_acid ( 120 ) , Ro31-8220 ( 129 , 162 ) , rolipram ( 15 , 49 ) , Rp-cAMPS ( 41 ) , Salidroside ( 15 ) , SB202190 ( 119 , 156 ) , SB203580 ( 47 , 145 , 146 , 153 , 162 , 164 ) , SB216763 ( 48 ) , selisistat ( 39 ) , semaxanib ( 156 ) , serum ( 150 ) , siRNA ( 8 , 19 , 115 ) , staurosporine ( 129 ) , sulprostone ( 59 ) , t-butanol ( 107 ) , tautomycin ( 130 ) , taxol ( 37 ) , TGF-beta ( 16 ) , TNF ( 53 , 142 , 162 ) , trichostatin_A ( 121 , 147 ) , U0126 ( 4 , 27 , 129 , 153 ) , UV ( 126 , 162 ) , vanadate ( 122 ) , VE-821 ( 28 ) , VEGF ( 156 ) , VIP ( 54 ) , virus infection ( 54 , 158 ) , wortmannin ( 27 , 59 , 132 )

Downstream Regulation
Effects of modification on CREB:	activity, induced ( 2 , 22 , 119 , 120 , 122 , 129 , 137 , 138 , 139 , 146 , 160 ) , molecular association, regulation ( 48 , 58 , 62 , 80 , 107 , 114 , 133 , 136 , 149 , 165 ) , phosphorylation ( 10 , 18 , 65 ) , protein degradation ( 23 )
Effects of modification on biological processes:	apoptosis, inhibited ( 160 ) , carcinogenesis, induced ( 8 , 19 , 26 ) , carcinogenesis, inhibited ( 7 ) , cell cycle regulation ( 7 ) , cell differentiation, altered ( 120 ) , cell differentiation, induced ( 29 ) , cell differentiation, inhibited ( 16 , 19 ) , cell growth, induced ( 62 ) , cell growth, inhibited ( 7 ) , cell motility, altered ( 72 ) , cell motility, induced ( 22 ) , DNA repair, induced ( 26 ) , neural plasticity ( 41 ) , signaling pathway regulation ( 12 , 18 , 22 ) , transcription, altered ( 19 , 80 , 120 , 129 , 133 , 137 , 149 , 165 ) , transcription, induced ( 2 , 4 , 11 , 15 , 21 , 29 , 30 , 39 , 58 , 62 , 107 , 114 , 122 , 127 , 138 , 139 , 140 , 144 , 164 , 166 ) , transcription, inhibited ( 16 ) , translation, inhibited ( 30 )
Induce interaction with:	CBP (human) ( 48 , 58 , 114 , 149 , 165 ) , DNA ( 114 , 133 ) , MEIS1 (human) ( 62 ) , Myb (human) ( 149 ) , Nur77 (human) ( 136 ) , RGS13 (human) ( 107 ) , SOX9 (human) ( 80 ) , p300 (human) ( 114 )

Disease / Diagnostics Relevance
Relevant diseases:	prostate cancer ( 19 , 142 )

References
1	Xu M, et al. (2024) Proteomic analysis reveals that cigarette smoke exposure diminishes ovarian reserve in mice by disrupting the CREB1-mediated ovarian granulosa cell proliferation-apoptosis balance. Ecotoxicol Environ Saf 271, 115989 38242047 Curated Info
2	Atsumi Y, et al. (2024) Repetitive CREB-DNA interactions at gene loci predetermined by CBP induce activity-dependent gene expression in human cortical neurons. Cell Rep 43, 113576 38128530 Curated Info
3	Lin TY, et al. (2023) Epinephrine inhibits PI3Kα via the Hippo kinases. Cell Rep 42, 113535 38060450 Curated Info
4	Tabrizian N, et al. (2023) ASCL1 is activated downstream of the ROR2/CREB signaling pathway to support lineage plasticity in prostate cancer. Cell Rep 42, 112937 37552603 Curated Info
5	Bei Y, et al. (2023) HIPK1 Inhibition Protects against Pathological Cardiac Hypertrophy by Inhibiting the CREB-C/EBPβ Axis. Adv Sci (Weinh) 10, e2300585 37098980 Curated Info
6	Lopez J, et al. (2023) The ribosomal S6 kinase 2 (RSK2)-SPRED2 complex regulates the phosphorylation of RSK substrates and MAPK signaling. J Biol Chem 299, 104789 37149146 Curated Info
7	Jayabal P, et al. (2023) Nitric oxide suppression by secreted frizzled-related protein 2 drives retinoblastoma. Cell Rep 42, 112103 36773293 Curated Info
8	Wu C, et al. (2023) Pancreatic cancer cells upregulate LPAR4 in response to isolation stress to promote an ECM-enriched niche and support tumour initiation. Nat Cell Biol 36646789 Curated Info
9	Chan J, et al. (2023) Systematic pharmacological analysis of agonistic and antagonistic fibroblast growth factor receptor 1 MAbs reveals a similar unique mode of action. J Biol Chem 299, 102729 36410439 Curated Info
10	Li H, et al. (2022) miR-200a-3p Regulates PRKACB and Participates in Aluminium-Induced Tau Phosphorylation in PC12 Cells. Neurotox Res 40, 1963-1978 36459375 Curated Info
11	Harada N, et al. (2022) Androgen receptor suppresses β-adrenoceptor-mediated CREB activation and thermogenesis in brown adipose tissue of male mice. J Biol Chem 298, 102619 36272644 Curated Info
12	Girdhar K, et al. (2022) Design, synthesis, and biological evaluation of a small molecule oral agonist of the glucagon-like-peptide-1 receptor. J Biol Chem, 101889 35378127 Curated Info
13	Abzianidze V, et al. (2022) Natural Phaeosphaeride A Derivatives Overcome Drug Resistance of Tumor Cells and Modulate Signaling Pathways. Pharmaceuticals (Basel) 15 35455394 Curated Info
14	Querfurth H, et al. (2022) A PDK-1 allosteric agonist neutralizes insulin signaling derangements and beta-amyloid toxicity in neuronal cells and in vitro. PLoS One 17, e0261696 35061720 Curated Info
15	Shrestha J, et al. (2022) HIV-1 gp120 Impairs Spatial Memory Through Cyclic AMP Response Element-Binding Protein. Front Aging Neurosci 14, 811481 35615594 Curated Info
16	Bell TJ, Nagel DJ, Woeller CF, Kottmann RM (2022) Ogerin mediated inhibition of TGF-β(1) induced myofibroblast differentiation is potentiated by acidic pH. PLoS One 17, e0271608 35901086 Curated Info
17	Zhang S, et al. (2021) AKAP13 couples GPCR signaling to mTORC1 inhibition. PLoS Genet 17, e1009832 34673774 Curated Info
18	Young BD, Sha J, Vashisht AA, Wohlschlegel JA (2021) Human Multisubunit E3 Ubiquitin Ligase Required for Heterotrimeric G-Protein β-Subunit Ubiquitination and Downstream Signaling. J Proteome Res 20, 4318-4330 34342229 Curated Info
19	Watson MJ, et al. (2021) Aberrant CREB1 activation in prostate cancer disrupts normal prostate luminal cell differentiation. Oncogene 33846571 Curated Info
20	Zhang J, et al. (2021) PKA-RIIβ autophosphorylation modulates PKA activity and seizure phenotypes in mice. Commun Biol 4, 263 33649504 Curated Info
21	Alasady MJ, et al. (2021) The calcium-binding protein S100B reduces IL6 production in malignant melanoma via inhibition of RSK cellular signaling. PLoS One 16, e0256238 34411141 Curated Info
22	Nagar H, et al. (2021) CRIF1 deficiency suppresses endothelial cell migration via upregulation of RhoGDI2. PLoS One 16, e0256646 34437633 Curated Info
23	Illiano M, et al. (2020) The KDM Inhibitor GSKJ4 Triggers CREB Downregulation via a Protein Kinase A and Proteasome-Dependent Mechanism in Human Acute Myeloid Leukemia Cells. Front Oncol 32582541 Curated Info
24	Terazawa S, Nakano M, Yamamoto A, Imokawa G (2020) Mycosporine-like amino acids stimulate hyaluronan secretion by up-regulating hyaluronan synthase 2 via activation of the p38/MSK1/CREB/c-Fos/AP-1 axis. J Biol Chem 32284328 Curated Info
25	Wu Y, et al. (2018) Novel Mechanism of Foxo1 Phosphorylation in Glucagon Signaling in Control of Glucose Homeostasis. Diabetes 30201683 Curated Info
26	Gökyildirim MY, et al. (2018) Targeting CREB-binding protein overrides LPS induced radioresistance in non-small cell lung cancer cell lines. Oncotarget 9, 28976-28988 29989005 Curated Info
27	Landeira BS, et al. (2018) Activity-Independent Effects of CREB on Neuronal Survival and Differentiation during Mouse Cerebral Cortex Development. Cereb Cortex 28, 538-548 27999124 Curated Info
28	Wolf Horrell EM, Jarrett SG, Carter KM, D'Orazio JA (2017) Divergence of cAMP signalling pathways mediating augmented nucleotide excision repair and pigment induction in melanocytes. Exp Dermatol 26, 577-584 28094871 Curated Info
29	Sang M, et al. (2016) GRK3 is a direct target of CREB activation and regulates neuroendocrine differentiation of prostate cancer cells. Oncotarget 7, 45171-45185 27191986 Curated Info
30	Xu J, et al. (2016) Inhibition of PHLPP2/cyclin D1 protein translation contributes to the tumor suppressive effect of NFκB2 (p100). Oncotarget 7, 34112-30 27095572 Curated Info
31	Hsu YL, et al. (2016) Lung cancer-derived galectin-1 contributes to cancer associated fibroblast-mediated cancer progression and immune suppression through TDO2/kynurenine axis. Oncotarget 7, 27584-98 27050278 Curated Info
32	Malkani N, et al. (2016) Increased IGFBP-1 phosphorylation in response to leucine deprivation is mediated by CK2 and PKC. Mol Cell Endocrinol 425, 48-60 26733150 Curated Info
33	Bullen JW, et al. (2016) Protein kinase A-dependent phosphorylation stimulates the transcriptional activity of hypoxia-inducible factor 1. Sci Signal 9, ra56 27245613 Curated Info
34	Cho K, et al. (2015) Calpain-mediated cleavage of DARPP-32 in Alzheimer's disease. Aging Cell 14, 878-86 26178297 Curated Info
35	Li CF, et al. (2015) The cAMP responsive element binding protein 1 transactivates epithelial membrane protein 2, a potential tumor suppressor in the urinary bladder urothelial carcinoma. Oncotarget 6, 9220-39 25940704 Curated Info
36	Tuominen I, et al. (2015) AIP inactivation leads to pituitary tumorigenesis through defective Gαi-cAMP signaling. Oncogene 34, 1174-84 24662816 Curated Info
37	Yin B, et al. (2015) The TrkB+ cancer stem cells contribute to post-chemotherapy recurrence of triple-negative breast cancers in an orthotopic mouse model. Oncogene 34, 761-70 24531713 Curated Info
38	Iessi E, et al. (2015) Death Receptor-Induced Apoptosis Signalling Regulation by Ezrin Is Cell Type Dependent and Occurs in a DISC-Independent Manner in Colon Cancer Cells. PLoS One 10, e0126526 26010871 Curated Info
39	Paz JC, et al. (2014) Combinatorial regulation of a signal-dependent activator by phosphorylation and acetylation. Proc Natl Acad Sci U S A 111, 17116-21 25404345 Curated Info
40	Ismail NA, Baines DL, Wilson SM (2014) The phosphorylation of endogenous Nedd4-2 In Na(+)-absorbing human airway epithelial cells. Eur J Pharmacol 732, 32-42 24657276 Curated Info
41	Sun WL, et al. (2014) Relapse to cocaine-seeking after abstinence is regulated by cAMP-dependent protein kinase A in the prefrontal cortex. Addict Biol 19, 77-86 23461423 Curated Info
42	Nardi F, et al. (2014) Enhanced Insulin Sensitivity Associated with Provision of Mono and Polyunsaturated Fatty Acids in Skeletal Muscle Cells Involves Counter Modulation of PP2A. PLoS One 9, e92255 24632852 Curated Info
43	Giansanti P, et al. (2013) Interrogating cAMP-dependent kinase signaling in Jurkat T cells via a protein kinase A targeted immune-precipitation phosphoproteomics approach. Mol Cell Proteomics 12, 3350-9 23882029 Curated Info
44	Stokes MP, et al. (2012) PTMScan Direct: Identification and Quantification of Peptides from Critical Signaling Proteins by Immunoaffinity Enrichment Coupled with LC-MS/MS. Mol Cell Proteomics 11, 187-201 22322096 Curated Info
45	Misra UK, Pizzo SV (2012) Upregulation of mTORC2 activation by the selective agonist of EPAC, 8-CPT-2Me-cAMP, in prostate cancer cells: assembly of a multiprotein signaling complex. J Cell Biochem 113, 1488-500 22173835 Curated Info
46	Yuasa K, Matsuda T, Tsuji A (2011) Functional regulation of transient receptor potential canonical 7 by cGMP-dependent protein kinase Iα. Cell Signal 23, 1179-87 21402151 Curated Info
47	Wang J, Zhou JY, Wu GS (2011) Bim protein degradation contributes to cisplatin resistance. J Biol Chem 286, 22384-92 21561860 Curated Info
48	Wang H, et al. (2011) Convergence of the mammalian target of rapamycin complex 1- and glycogen synthase kinase 3-β-signaling pathways regulates the innate inflammatory response. J Immunol 186, 5217-26 21422248 Curated Info
49	Marquette A, et al. (2011) ERK and PDE4 cooperate to induce RAF isoform switching in melanoma. Nat Struct Mol Biol 18, 584-91 21478863 Curated Info
50	Wang CG, et al. (2011) Activation of the spinal extracellular signal-regulated kinase 5 signaling pathway contributes to morphine physical dependence in rats. Neurosci Lett 494, 38-43 21356274 Curated Info
51	Moon JS, et al. (2010) Androgen stimulates glycolysis for de novo lipid synthesis by increasing the activities of hexokinase 2 and 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase 2 in prostate cancer cells. Biochem J 433, 225-33 20958264 Curated Info
52	Moritz A (2010) CST Curation Set: 10607; Year: 2010; Biosample/Treatment: cell line, MKN-45/Su11274; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY] Curated Info
53	Gao N, et al. (2010) A-kinase-interacting protein 1 (AKIP1) acts as a molecular determinant of PKA in NF-kappaB signaling. J Biol Chem 285, 28097-104 20562110 Curated Info
54	Liu X, et al. (2010) Phorbol ester-induced human cytomegalovirus major immediate-early (MIE) enhancer activation through PKC-delta, CREB, and NF-kappaB desilences MIE gene expression in quiescently infected human pluripotent NTera2 cells. J Virol 84, 8495-508 20504934 Curated Info
55	Possemato A (2010) CST Curation Set: 10290; Year: 2010; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Curated Info
56	Possemato A (2010) CST Curation Set: 10293; Year: 2010; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Curated Info
57	Possemato A (2010) CST Curation Set: 10288; Year: 2010; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Curated Info
58	Sakamoto K, et al. (2010) Regulation of genotoxic stress response by homeodomain-interacting protein kinase 2 through phosphorylation of cyclic AMP response element-binding protein at serine 271. Mol Biol Cell 21, 2966-74 20573984 Curated Info
59	Wang P, Zhu F, Lee NH, Konstantopoulos K (2010) Shear-induced interleukin-6 synthesis in chondrocytes: roles of E prostanoid (EP) 2 and EP3 in cAMP/protein kinase A- and PI3-K/Akt-dependent NF-kappaB activation. J Biol Chem 285, 24793-804 20516073 Curated Info
60	Beausoleil S (2010) CST Curation Set: 10287; Year: 2010; Biosample/Treatment: cell line, K-562/untreated; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Curated Info
61	Friedrich MW, et al. (2010) Imaging CREB activation in living cells. J Biol Chem 285, 23285-95 20484048 Curated Info
62	Wang Z, et al. (2010) GSK-3 promotes conditional association of CREB and its coactivators with MEIS1 to facilitate HOX-mediated transcription and oncogenesis. Cancer Cell 17, 597-608 20541704 Curated Info
63	Law M, Corsino P, Parker NT, Law BK (2010) Identification of a small molecule inhibitor of serine 276 phosphorylation of the p65 subunit of NF-kappaB using in silico molecular docking. Cancer Lett 291, 217-24 19910110 Curated Info
64	Kang M, Ross GR, Akbarali HI (2010) The effect of tyrosine nitration of L-type Ca2+ channels on excitation-transcription coupling in colonic inflammation. Br J Pharmacol 159, 1226-35 20128810 Curated Info
65	Shimada M, Nakadai T, Fukuda A, Hisatake K (2010) cAMP-response element-binding protein (CREB) controls MSK1-mediated phosphorylation of histone H3 at the c-fos promoter in vitro. J Biol Chem 285, 9390-401 20089855 Curated Info
66	Moritz A (2010) CST Curation Set: 9280; Year: 2010; Biosample/Treatment: cell line, MKN-45/DMSO &'\|\|' Su11274; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY]) Curated Info
67	Moritz A (2010) CST Curation Set: 9235; Year: 2010; Biosample/Treatment: cell line, MKN-45/calyculin_A & pervanadate; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY]) Curated Info
68	Moritz A (2010) CST Curation Set: 9244; Year: 2010; Biosample/Treatment: cell line, HeLa/UV; Disease: cervical adenocarcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY]) Curated Info
69	Moritz A (2010) CST Curation Set: 9241; Year: 2010; Biosample/Treatment: cell line, NCI-H1703/untreated; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY]) Curated Info
70	Wu B, Jiang P, Mu Y, Wilmouth RC (2009) Cancer Osaka thyroid (Cot) phosphorylates Polo-like kinase (PLK1) at Ser137 but not at Thr210. Biol Chem 390, 1271-7 19804365 Curated Info
71	Zhang YW, et al. (2009) A functional mouse retroposed gene Rps23r1 reduces Alzheimer's beta-amyloid levels and tau phosphorylation. Neuron 64, 328-40 19914182 Curated Info
72	Hansen C, et al. (2009) Wnt-5a-induced phosphorylation of DARPP-32 inhibits breast cancer cell migration in a CREB-dependent manner. J Biol Chem 284, 27533-43 19651774 Curated Info
73	Zhong D, et al. (2009) The Glycolytic Inhibitor 2-Deoxyglucose Activates Multiple Prosurvival Pathways through IGF1R. J Biol Chem 284, 23225-33 19574224 Curated Info
74	Possemato A (2009) CST Curation Set: 7130; Year: 2009; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Curated Info
75	Possemato A (2009) CST Curation Set: 7128; Year: 2009; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Curated Info
76	Possemato A (2009) CST Curation Set: 7126; Year: 2009; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Curated Info
77	Possemato A (2009) CST Curation Set: 7124; Year: 2009; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Curated Info
78	Possemato A (2009) CST Curation Set: 7122; Year: 2009; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: (K/R)XpSX(K/R) Curated Info
79	Possemato A (2009) CST Curation Set: 7120; Year: 2009; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: (K/R)XpSX(K/R)Antibodies Used to Purify Peptides prior to LCMS: Phospho-(Ser) PKC Substrate Antibody Cat#: 2261, PTMScan(R) Phospho-PKC Substrate Motif (K/RXpSXK/R) Immunoaffinity Beads Cat#: 1985 Curated Info
80	Zhao L, Li G, Zhou GQ (2009) SOX9 directly binds CREB as a novel synergism with the PKA pathway in BMP-2-induced osteochondrogenic differentiation. J Bone Miner Res 24, 826-36 19113914 Curated Info
81	Inglis SK, et al. (2009) SGK1 activity in Na(+) absorbing airway epithelial cells monitored by assaying NDRG1-Thr(346/356/366) phosphorylation. Pflugers Arch 457, 1287-301 18787837 Curated Info
82	Zhou J (2009) CST Curation Set: 6342; Year: 2009; Biosample/Treatment: cell line, HeLa/UV; Disease: cervical adenocarcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-(Ser/Thr) PKD Substrate Antibody Cat#: 4381, PTMScan(R) Phospho-PKD Substrate Motif (LXRXXpS/pT) Immunoaffinity Beads Cat#: 1986 Curated Info
83	Guo A (2009) CST Curation Set: 6062; Year: 2009; Biosample/Treatment: cell line, 293/Insulin; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS/T) (110B7) Rabbit mAb Cat#: 9614, PTMScan(R) Phospho-Akt Substrate Motif (RXXS/T) Immunoaffinity Beads Cat#: 1978 Curated Info
84	Guo A (2009) CST Curation Set: 6061; Year: 2009; Biosample/Treatment: cell line, 293/rapamycin; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS/T) (110B7) Rabbit mAb Cat#: 9614, PTMScan(R) Phospho-Akt Substrate Motif (RXXS/T) Immunoaffinity Beads Cat#: 1978 Curated Info
85	Guo A (2009) CST Curation Set: 6060; Year: 2009; Biosample/Treatment: cell line, 293/Torin; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS/T) (110B7) Rabbit mAb Cat#: 9614, PTMScan(R) Phospho-Akt Substrate Motif (RXXS/T) Immunoaffinity Beads Cat#: 1978 Curated Info
86	Guo A (2009) CST Curation Set: 6059; Year: 2009; Biosample/Treatment: cell line, 293/control; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS/T) (110B7) Rabbit mAb Cat#: 9614, PTMScan(R) Phospho-Akt Substrate Motif (RXXS/T) Immunoaffinity Beads Cat#: 1978 Curated Info
87	Zhou J (2009) CST Curation Set: 5902; Year: 2009; Biosample/Treatment: cell line, Jurkat/untreated; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: (K/R)XpSX(K/R)Antibodies Used to Purify Peptides prior to LCMS: Phospho-(Ser) PKC Substrate Antibody Cat#: 2261, PTMScan(R) Phospho-PKC Substrate Motif (K/RXpSXK/R) Immunoaffinity Beads Cat#: 1985 Curated Info
88	Zhou J (2009) CST Curation Set: 5904; Year: 2009; Biosample/Treatment: cell line, Jurkat/TPA; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: (K/R)XpSX(K/R)Antibodies Used to Purify Peptides prior to LCMS: Phospho-(Ser) PKC Substrate Antibody Cat#: 2261, PTMScan(R) Phospho-PKC Substrate Motif (K/RXpSXK/R) Immunoaffinity Beads Cat#: 1985 Curated Info
89	Zhou J (2009) CST Curation Set: 5901; Year: 2009; Biosample/Treatment: cell line, Jurkat/TPA; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: (K/R)XpSX(K/R)Antibodies Used to Purify Peptides prior to LCMS: Phospho-(Ser) PKC Substrate Antibody Cat#: 2261, PTMScan(R) Phospho-PKC Substrate Motif (K/RXpSXK/R) Immunoaffinity Beads Cat#: 1985 Curated Info
90	Zhou J (2009) CST Curation Set: 5903; Year: 2009; Biosample/Treatment: cell line, Jurkat/untreated; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: (K/R)XpSX(K/R)Antibodies Used to Purify Peptides prior to LCMS: Phospho-(Ser) PKC Substrate Antibody Cat#: 2261, PTMScan(R) Phospho-PKC Substrate Motif (K/RXpSXK/R) Immunoaffinity Beads Cat#: 1985 Curated Info
91	Zhou J (2009) CST Curation Set: 5905; Year: 2009; Biosample/Treatment: cell line, Jurkat/TPA; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: (K/R)XpSX(K/R)Antibodies Used to Purify Peptides prior to LCMS: Phospho-(Ser) PKC Substrate Antibody Cat#: 2261, PTMScan(R) Phospho-PKC Substrate Motif (K/RXpSXK/R) Immunoaffinity Beads Cat#: 1985 Curated Info
92	Zhou J (2009) CST Curation Set: 5900; Year: 2009; Biosample/Treatment: cell line, Jurkat/TPA; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: (K/R)XpSX(K/R)Antibodies Used to Purify Peptides prior to LCMS: Phospho-(Ser) PKC Substrate Antibody Cat#: 2261, PTMScan(R) Phospho-PKC Substrate Motif (K/RXpSXK/R) Immunoaffinity Beads Cat#: 1985 Curated Info
93	Zhou J (2009) CST Curation Set: 5896; Year: 2009; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: (K/R)XpSX(K/R)Antibodies Used to Purify Peptides prior to LCMS: Phospho-(Ser) PKC Substrate Antibody Cat#: 2261, PTMScan(R) Phospho-PKC Substrate Motif (K/RXpSXK/R) Immunoaffinity Beads Cat#: 1985 Curated Info
94	Zhou J (2009) CST Curation Set: 5898; Year: 2009; Biosample/Treatment: cell line, Jurkat/untreated; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: (K/R)XpSX(K/R)Antibodies Used to Purify Peptides prior to LCMS: Phospho-(Ser) PKC Substrate Antibody Cat#: 2261, PTMScan(R) Phospho-PKC Substrate Motif (K/RXpSXK/R) Immunoaffinity Beads Cat#: 1985 Curated Info
95	Zhou J (2009) CST Curation Set: 5897; Year: 2009; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: (K/R)XpSX(K/R)Antibodies Used to Purify Peptides prior to LCMS: Phospho-(Ser) PKC Substrate Antibody Cat#: 2261, PTMScan(R) Phospho-PKC Substrate Motif (K/RXpSXK/R) Immunoaffinity Beads Cat#: 1985 Curated Info
96	Denison FC, Hiscock NJ, Carling D, Woods A (2009) Characterization of an alternative splice variant of LKB1. J Biol Chem 284, 67-76 18854309 Curated Info
97	Possemato A (2008) CST Curation Set: 5542; Year: 2008; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Curated Info
98	Zhou J (2008) CST Curation Set: 5474; Year: 2008; Biosample/Treatment: cell line, Jurkat/TPA; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: (K/R)XpSX(K/R)Antibodies Used to Purify Peptides prior to LCMS: Phospho-(Ser) PKC Substrate Antibody Cat#: 2261, PTMScan(R) Phospho-PKC Substrate Motif (K/RXpSXK/R) Immunoaffinity Beads Cat#: 1985 Curated Info
99	Zhou J (2008) CST Curation Set: 5475; Year: 2008; Biosample/Treatment: cell line, Jurkat/TPA; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: (K/R)XpSX(K/R)Antibodies Used to Purify Peptides prior to LCMS: Phospho-(Ser) PKC Substrate Antibody Cat#: 2261, PTMScan(R) Phospho-PKC Substrate Motif (K/RXpSXK/R) Immunoaffinity Beads Cat#: 1985 Curated Info
100	Zhou J (2008) CST Curation Set: 5466; Year: 2008; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: (K/R)XpSX(K/R)Antibodies Used to Purify Peptides prior to LCMS: Phospho-(Ser) PKC Substrate Antibody Cat#: 2261, PTMScan(R) Phospho-PKC Substrate Motif (K/RXpSXK/R) Immunoaffinity Beads Cat#: 1985 Curated Info
101	Zhou J (2008) CST Curation Set: 5467; Year: 2008; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: (K/R)XpSX(K/R)Antibodies Used to Purify Peptides prior to LCMS: Phospho-(Ser) PKC Substrate Antibody Cat#: 2261, PTMScan(R) Phospho-PKC Substrate Motif (K/RXpSXK/R) Immunoaffinity Beads Cat#: 1985 Curated Info
102	Zhou J (2008) CST Curation Set: 5470; Year: 2008; Biosample/Treatment: cell line, Jurkat/TPA; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: (K/R)XpSX(K/R)Antibodies Used to Purify Peptides prior to LCMS: Phospho-(Ser) PKC Substrate Antibody Cat#: 2261, PTMScan(R) Phospho-PKC Substrate Motif (K/RXpSXK/R) Immunoaffinity Beads Cat#: 1985 Curated Info
103	Zhou J (2008) CST Curation Set: 5314; Year: 2008; Biosample/Treatment: cell line, Jurkat/TPA; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: (K/R)XpSX(K/R)Antibodies Used to Purify Peptides prior to LCMS: Phospho-(Ser) PKC Substrate Antibody Cat#: 2261, PTMScan(R) Phospho-PKC Substrate Motif (K/RXpSXK/R) Immunoaffinity Beads Cat#: 1985 Curated Info
104	Zhou J (2008) CST Curation Set: 5306; Year: 2008; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: (K/R)XpSX(K/R)Antibodies Used to Purify Peptides prior to LCMS: Phospho-(Ser) PKC Substrate Antibody Cat#: 2261, PTMScan(R) Phospho-PKC Substrate Motif (K/RXpSXK/R) Immunoaffinity Beads Cat#: 1985 Curated Info
105	Zhou J (2008) CST Curation Set: 5308; Year: 2008; Biosample/Treatment: cell line, Jurkat/untreated; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: (K/R)XpSX(K/R)Antibodies Used to Purify Peptides prior to LCMS: Phospho-(Ser) PKC Substrate Antibody Cat#: 2261, PTMScan(R) Phospho-PKC Substrate Motif (K/RXpSXK/R) Immunoaffinity Beads Cat#: 1985 Curated Info
106	Stokes M (2008) CST Curation Set: 5165; Year: 2008; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RRXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-PKA Substrate (RRXS/T) (100G7) Rabbit mAb Cat#: 9624, PTMScan(R) Phospho-PKA Substrate Motif (K/RK/RXS/T) Immunoaffinity Beads Cat#: 1984 Curated Info
107	Xie Z, et al. (2008) RGS13 acts as a nuclear repressor of CREB. Mol Cell 31, 660-70 18775326 Curated Info
108	Possemato A (2008) CST Curation Set: 4819; Year: 2008; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Curated Info
109	Possemato A (2008) CST Curation Set: 4826; Year: 2008; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: (K/R)XpSX(K/R)Antibodies Used to Purify Peptides prior to LCMS: Phospho-(Ser) PKC Substrate Antibody Cat#: 2261, PTMScan(R) Phospho-PKC Substrate Motif (K/RXpSXK/R) Immunoaffinity Beads Cat#: 1985 Curated Info
110	Possemato A (2008) CST Curation Set: 4827; Year: 2008; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: (K/R)XpSX(K/R)Antibodies Used to Purify Peptides prior to LCMS: Phospho-(Ser) PKC Substrate Antibody Cat#: 2261, PTMScan(R) Phospho-PKC Substrate Motif (K/RXpSXK/R) Immunoaffinity Beads Cat#: 1985 Curated Info
111	Possemato A (2008) CST Curation Set: 4828; Year: 2008; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: (K/R)XpSX(K/R)Antibodies Used to Purify Peptides prior to LCMS: Phospho-(Ser) PKC Substrate Antibody Cat#: 2261, PTMScan(R) Phospho-PKC Substrate Motif (K/RXpSXK/R) Immunoaffinity Beads Cat#: 1985 Curated Info
112	Possemato A (2008) CST Curation Set: 4831; Year: 2008; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RRXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-PKA Substrate (RRXS/T) (100G7) Rabbit mAb Cat#: 9624, PTMScan(R) Phospho-PKA Substrate Motif (K/RK/RXS/T) Immunoaffinity Beads Cat#: 1984 Curated Info
113	Possemato A (2008) CST Curation Set: 4832; Year: 2008; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RRXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-PKA Substrate (RRXS/T) (100G7) Rabbit mAb Cat#: 9624, PTMScan(R) Phospho-PKA Substrate Motif (K/RK/RXS/T) Immunoaffinity Beads Cat#: 1984 Curated Info
114	Geiger TR, Sharma N, Kim YM, Nyborg JK (2008) The human T-cell leukemia virus type 1 tax protein confers CBP/p300 recruitment and transcriptional activation properties to phosphorylated CREB. Mol Cell Biol 28, 1383-92 18070920 Curated Info
115	Belkhiri A, et al. (2008) t-Darpp promotes cancer cell survival by up-regulation of Bcl2 through Akt-dependent mechanism. Cancer Res 68, 395-403 18199533 Curated Info
116	Böer U, et al. (2007) Enhancement by lithium of cAMP-induced CRE/CREB-directed gene transcription conferred by TORC on the CREB basic leucine zipper domain. Biochem J 408, 69-77 17696880 Curated Info
117	Rose AJ, et al. (2007) Effect of endurance exercise training on Ca2+ calmodulin-dependent protein kinase II expression and signalling in skeletal muscle of humans. J Physiol 583, 785-95 17627985 Curated Info
118	Gesser B, et al. (2007) Dimethylfumarate specifically inhibits the mitogen and stress-activated kinases 1 and 2 (MSK1/2): possible role for its anti-psoriatic effect. J Invest Dermatol 127, 2129-37 17495961 Curated Info
119	Funding AT, Johansen C, Kragballe K, Iversen L (2007) Mitogen- and stress-activated protein kinase 2 and cyclic AMP response element binding protein are activated in lesional psoriatic epidermis. J Invest Dermatol 127, 2012-9 17429437 Curated Info
120	Fernandes ND, Sun Y, Price BD (2007) Activation of the kinase activity of ATM by retinoic acid is required for CREB-dependent differentiation of neuroblastoma cells. J Biol Chem 282, 16577-84 17426037 Curated Info
121	Keller MJ, et al. (2007) Reversal of human cytomegalovirus major immediate-early enhancer/promoter silencing in quiescently infected cells via the cyclic AMP signaling pathway. J Virol 81, 6669-81 17301150 Curated Info
122	Johannessen M, et al. (2007) Protein kinase D induces transcription through direct phosphorylation of the cAMP-response element-binding protein. J Biol Chem 282, 14777-87 17389598 Curated Info
123	Possemato A (2007) CST Curation Set: 2929; Year: 2007; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RRXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-PKA Substrate (RRXS/T) (100G7) Rabbit mAb Cat#: 9624, PTMScan(R) Phospho-PKA Substrate Motif (K/RK/RXS/T) Immunoaffinity Beads Cat#: 1984 Curated Info
124	Possemato A (2007) CST Curation Set: 2721; Year: 2007; Biosample/Treatment: cell line, K562/untreated; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: (K/R)XpSX(K/R) Antibodies Used to Purify Peptides prior to LCMS: Phospho-(Ser) PKC Substrate Antibody Cat#: 2261, PTMScan(R) Phospho-PKC Substrate Motif (K/RXpSXK/R) Immunoaffinity Beads Cat#: 1985 Curated Info
125	Sjögren B, Hamblin MW, Svenningsson P (2006) Cholesterol depletion reduces serotonin binding and signaling via human 5-HT(7(a)) receptors. Eur J Pharmacol 552, 1-10 17064686 Curated Info
126	Sastry KS, Karpova Y, Kulik G (2006) Epidermal growth factor protects prostate cancer cells from apoptosis by inducing BAD phosphorylation via redundant signaling pathways. J Biol Chem 281, 27367-77 16847055 Curated Info
127	Ohmae S, et al. (2006) Molecular identification and characterization of a family of kinases with homology to Ca2+/calmodulin-dependent protein kinases I/IV. J Biol Chem 281, 20427-39 16684769 Curated Info
128	Hoffmann KM, Tapia JA, Jensen RT (2006) Activation of Gab1 in pancreatic acinar cells: effects of gastrointestinal growth factors/hormones on stimulation, phosphospecific phosphorylation, translocation and interaction with downstream signaling molecules. Cell Signal 18, 942-54 16185843 Curated Info
129	White PC, et al. (2006) Regulation of cyclin D2 and the cyclin D2 promoter by protein kinase A and CREB in lymphocytes. Oncogene 25, 2170-80 16301994 Curated Info
130	Szatmari E, et al. (2005) A positive feedback loop between glycogen synthase kinase 3beta and protein phosphatase 1 after stimulation of NR2B NMDA receptors in forebrain neurons. J Biol Chem 280, 37526-35 16155008 Curated Info
131	Chen X, et al. (2005) TSSK5, a novel member of the testis-specific serine/threonine kinase family, phosphorylates CREB at Ser-133, and stimulates the CRE/CREB responsive pathway. Biochem Biophys Res Commun 333, 742-9 15964553 Curated Info
132	Fujino H, Salvi S, Regan JW (2005) Differential regulation of phosphorylation of the cAMP response element-binding protein after activation of EP2 and EP4 prostanoid receptors by prostaglandin E2. Mol Pharmacol 68, 251-9 15855407 Curated Info
133	Zhang X, et al. (2005) Genome-wide analysis of cAMP-response element binding protein occupancy, phosphorylation, and target gene activation in human tissues. Proc Natl Acad Sci U S A 102, 4459-64 15753290 Curated Info
134	David S, Kalb RG (2005) Serum/glucocorticoid-inducible kinase can phosphorylate the cyclic AMP response element binding protein, CREB. FEBS Lett 579, 1534-8 15733869 Curated Info
135	Jin SH, Blendy JA, Thomas SA (2005) Cyclic AMP response element-binding protein is required for normal maternal nurturing behavior. Neuroscience 133, 647-55 15893884 Curated Info
136	Mynard V, et al. (2004) Synergistic signaling by corticotropin-releasing hormone and leukemia inhibitory factor bridged by phosphorylated 3',5'-cyclic adenosine monophosphate response element binding protein at the Nur response element (NurRE)-signal transducers and activators of transcription (STAT) element of the proopiomelanocortin promoter. Mol Endocrinol 18, 2997-3010 15319449 Curated Info
137	Screaton RA, et al. (2004) The CREB coactivator TORC2 functions as a calcium- and cAMP-sensitive coincidence detector. Cell 119, 61-74 15454081 Curated Info
138	Shi Y, et al. (2004) Direct regulation of CREB transcriptional activity by ATM in response to genotoxic stress. Proc Natl Acad Sci U S A 101, 5898-903 15073328 Curated Info
139	Hansen TO, Rehfeld JF, Nielsen FC (2004) GSK-3beta reduces cAMP-induced cholecystokinin gene expression by inhibiting CREB binding. Neuroreport 15, 841-5 15073527 Curated Info
140	Lewis-Tuffin LJ, Quinn PG, Chikaraishi DM (2004) Tyrosine hydroxylase transcription depends primarily on cAMP response element activity, regardless of the type of inducing stimulus. Mol Cell Neurosci 25, 536-47 15033181 Curated Info
141	Hahm SH, Chen Y, Vinson C, Eiden LE (2003) A calcium-initiated signaling pathway propagated through calcineurin and cAMP response element-binding protein activates proenkephalin gene transcription after depolarization. Mol Pharmacol 64, 1503-11 14645681 Curated Info
142	Salas TR, et al. (2003) Alleviating the suppression of glycogen synthase kinase-3beta by Akt leads to the phosphorylation of cAMP-response element-binding protein and its transactivation in intact cell nuclei. J Biol Chem 278, 41338-46 12900420 Curated Info
143	Elliott MR, Tolnay M, Tsokos GC, Kammer GM (2003) Protein kinase A regulatory subunit type II beta directly interacts with and suppresses CREB transcriptional activity in activated T cells. J Immunol 171, 3636-44 14500661 Curated Info
144	Conkright MD, et al. (2003) TORCs: transducers of regulated CREB activity. Mol Cell 12, 413-23 14536081 Curated Info
145	Lee CW, et al. (2003) Lysophosphatidic acid stimulates CREB through mitogen- and stress-activated protein kinase-1. Biochem Biophys Res Commun 305, 455-61 12763014 Curated Info
146	Bébien M, et al. (2003) Immediate-early gene induction by the stresses anisomycin and arsenite in human osteosarcoma cells involves MAPK cascade signaling to Elk-1, CREB and SRF. Oncogene 22, 1836-47 12660819 Curated Info
147	Canettieri G, et al. (2003) Attenuation of a phosphorylation-dependent activator by an HDAC-PP1 complex. Nat Struct Biol 10, 175-81 12567184 Curated Info
148	Li K, Zhao S, Karur V, Wojchowski DM (2002) DYRK3 activation, engagement of protein kinase A/cAMP response element-binding protein, and modulation of progenitor cell survival. J Biol Chem 277, 47052-60 12356771 Curated Info
149	Zor T, et al. (2002) Roles of phosphorylation and helix propensity in the binding of the KIX domain of CREB-binding protein by constitutive (c-Myb) and inducible (CREB) activators. J Biol Chem 277, 42241-8 12196545 Curated Info
150	Zeng H, Liu Y, Templeton DM (2002) Ca(2+)/calmodulin-dependent and cAMP-dependent kinases in induction of c-fos in human mesangial cells. Am J Physiol Renal Physiol 283, F888-94 12372763 Curated Info
151	Amorino GP, et al. (2002) Epidermal growth factor receptor dependence of radiation-induced transcription factor activation in human breast carcinoma cells. Mol Biol Cell 13, 2233-44 12134064 Curated Info
152	Shelly C, Herrera R (2002) Activation of SGK1 by HGF, Rac1 and integrin-mediated cell adhesion in MDCK cells: PI-3K-dependent and -independent pathways. J Cell Sci 115, 1985-93 11956329 Curated Info
153	Cammarota M, Bevilaqua LR, Dunkley PR, Rostas JA (2001) Angiotensin II promotes the phosphorylation of cyclic AMP-responsive element binding protein (CREB) at Ser133 through an ERK1/2-dependent mechanism. J Neurochem 79, 1122-8 11752053 Curated Info
154	Gubina E, et al. (2001) betac cytokine receptor-induced stimulation of cAMP response element binding protein phosphorylation requires protein kinase C in myeloid cells: a novel cytokine signal transduction cascade. J Immunol 167, 4303-10 11591753 Curated Info
155	Grimes CA, Jope RS (2001) CREB DNA binding activity is inhibited by glycogen synthase kinase-3 beta and facilitated by lithium. J Neurochem 78, 1219-32 11579131 Curated Info
156	Mayo LD, et al. (2001) Vascular endothelial cell growth factor activates CRE-binding protein by signaling through the KDR receptor tyrosine kinase. J Biol Chem 276, 25184-9 11335727 Curated Info
157	Harum KH, Alemi L, Johnston MV (2001) Cognitive impairment in Coffin-Lowry syndrome correlates with reduced RSK2 activation. Neurology 56, 207-14 11160957 Curated Info
158	Routes JM, Colton LA, Ryan S, Klemm DJ (2000) CREB (cAMP response element binding protein) and C/EBPalpha (CCAAT/enhancer binding protein) are required for the superstimulation of phosphoenolpyruvate carboxykinase gene transcription by adenoviral E1a and cAMP. Biochem J 352 Pt 2, 335-42 11085926 Curated Info
159	Frödin M, Jensen CJ, Merienne K, Gammeltoft S (2000) A phosphoserine-regulated docking site in the protein kinase RSK2 that recruits and activates PDK1. EMBO J 19, 2924-34 10856237 Curated Info
160	Bonni A, et al. (1999) Cell survival promoted by the Ras-MAPK signaling pathway by transcription-dependent and -independent mechanisms. Science 286, 1358-62 10558990 Curated Info
161	Swanson KD, et al. (1999) Transcription factor phosphorylation by pp90(rsk2). Identification of Fos kinase and NGFI-B kinase I as pp90(rsk2). J Biol Chem 274, 3385-95 9920881 Curated Info
162	Deak M, Clifton AD, Lucocq LM, Alessi DR (1998) Mitogen- and stress-activated protein kinase-1 (MSK1) is directly activated by MAPK and SAPK2/p38, and may mediate activation of CREB. EMBO J 17, 4426-41 9687510 Curated Info
163	Xing J, et al. (1998) Nerve growth factor activates extracellular signal-regulated kinase and p38 mitogen-activated protein kinase pathways to stimulate CREB serine 133 phosphorylation. Mol Cell Biol 18, 1946-55 9528766 Curated Info
164	Tan Y, et al. (1996) FGF and stress regulate CREB and ATF-1 via a pathway involving p38 MAP kinase and MAPKAP kinase-2. EMBO J 15, 4629-42 8887554 Curated Info
165	Parker D, et al. (1996) Phosphorylation of CREB at Ser-133 induces complex formation with CREB-binding protein via a direct mechanism. Mol Cell Biol 16, 694-703 8552098 Curated Info
166	Thompson MA, Ginty DD, Bonni A, Greenberg ME (1995) L-type voltage-sensitive Ca2+ channel activation regulates c-fos transcription at multiple levels. J Biol Chem 270, 4224-35 7876182 Curated Info
167	Fiol CJ, et al. (1994) A secondary phosphorylation of CREB341 at Ser129 is required for the cAMP-mediated control of gene expression. A role for glycogen synthase kinase-3 in the control of gene expression. J Biol Chem 269, 32187-93 7798217 Curated Info